Bone: Will breast cancer chemoprevention stand on 'solid bone'?
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Aromatase inhibitors are the most effective agents for preventing breast cancer; however, their use is associated with bone loss and an increased risk of fractures. Sestak and colleagues show that administration of an oral bisphosphonate prevents aromatase-inhibitor-induced bone loss in postmenopausal women with osteopenia or osteoporosis who are at high risk of breast cancer.